Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Investigation Of Vesicular-Mediated Transport Of Intercellular Adhesion Molecule-1-Targeted Carriers For Treatment Of Lysosomal Storage Disorders

R. L. Manthe
Published 2017 · Materials Science

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Title of Dissertation: INVESTIGATION OF VESICULARMEDIATED TRANSPORT OF INTERCELLULAR ADHESION MOLECULE1-TARGETED CARRIERS FOR TREATMENT OF LYSOSOMAL STORAGE DISORDERS Rachel Lee Manthe, Doctor of Philosophy, 2017 Dissertation directed by: Associate Professor, Silvia Muro Fischell Department of Bioengineering & Institute for Bioscience and Biotechnology Research Numerous cellular processes and therapeutic interventions rely on vesicularmediated endocytosis to gain entry into cells and sub-cellular compartments, as well as for transcellular transport across biological barriers such as found at the blood-brain interface. Yet, endocytic behavior can be altered in disease, representing an additional hurdle in the design of effective therapeutic strategies. Lysosomal storage disorders (LSDs), characterized by lysosomal accumulation of undigested substrates as a result of deficient enzymatic activity, illustrate this paradigm. Currently, intravenous infusion of recombinant lysosomal enzymes to replace those deficient is the standard clinical approach for these disorders. However, clathrin-mediated endocytosis utilized by replacement enzymes for cellular uptake and lysosomal trafficking is altered, thereby impacting treatment efficacy as recently demonstrated in acid sphingomyelinase-deficient type A Niemann-Pick disease (NPD). Therefore, alternative means to bypass defunct routes is warranted. Therapeutic delivery via polymer nanocarriers targeting intercellular adhesion molecule-1 (anti-ICAM NCs), a cell-surface molecule overexpressed in endothelial and subjacent tissue cells during inflammation, such as in LSDs, represents a viable option since it permits uptake, intraand transcellular transport via a unique endocytic route called the cell adhesion molecule (CAM) pathway. In this dissertation, cell culture and animal models were used to examine the (1) endocytic activity of the CAM pathway and other clathrin-independent routes in type A NPD, (2) role of targeting valency (i.e., density of ICAM-1-targeting molecules on the NC surface) in regulating the CAM pathway, and (3) effects induced via engagement of ICAM-1 on cells by anti-ICAM NCs. The results herein demonstrate the CAM pathway is more active in diseased cells compared to other classical endocytic pathways, making it the most amenable route for therapeutic enzyme replacement. Further, modulating targeting valency of NCs optimized this strategy for enhanced enzyme delivery to the brain, a target organ for type A NPD. Lastly, anti-ICAM NCs attenuated endothelial release of soluble ICAM-1, an inflammatory regulator, representing a secondary benefit of this system. Overall, this work validates utility of anti-ICAM NCs for enzyme replacement to treat NPD and likely other LSDs, and provides insight into biological processes and design parameters that influence the therapeutic efficacy of targeted drug carriers. INVESTIGATION OF VESICULAR-MEDIATED TRANSPORT OF INTERCELLULAR ADHESION MOLECULE-1-TARGETED CARRIERS FOR TREATMENT OF LYSOSOMAL STORAGE DISORDERS
This paper references
10.1086/345074
The demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new genotype/phenotype correlations.
C. Simonaro (2002)
10.1016/j.bbamcr.2008.12.001
Lysosomal disorders: from storage to cellular damage.
A. Ballabio (2009)
10.1016/S0003-2697(02)00629-2
A fluorescence-based, high-performance liquid chromatographic assay to determine acid sphingomyelinase activity and diagnose types A and B Niemann-Pick disease.
X. He (2003)
10.1158/1535-7163.MCT-11-0047
The Role of Autophagy in Cancer: Therapeutic Implications
Z. J. Yang (2011)
Hernandez-Trejo, The impact of nanobiotechnology on the development of new drug delivery systems
O. Kayser (2005)
10.1038/mt.2008.119
Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product.
Mark J. Osborn (2008)
10.1016/J.YMTHE.2005.02.031
Defining the pathway for Tat-mediated delivery of beta-glucuronidase in cultured cells and MPS VII mice.
K. Orii (2005)
10.1096/fj.04-2747rev
Nanomedicine: current status and future prospects
S. Moghimi (2005)
10.1111/cge.12076
Identification of seven novel SMPD1 mutations causing Niemann–Pick disease types A and B
P. Irún (2013)
10.1007/s10571-004-1375-x
In Search of the Astrocytic Factor(s) Modulating Blood–Brain Barrier Functions in Brain Capillary Endothelial Cells In Vitro
R. Haseloff (2004)
10.1021/mp800051m
Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles
F. Alexis (2008)
10.1016/J.JACC.2003.07.048
Intravascular ultrasound molecular imaging of atheroma components in vivo.
A. Hamilton (2004)
10.1242/jcs.034298
Inhibitors of the V0 subunit of the vacuolar H+-ATPase prevent segregation of lysosomal- and secretory-pathway proteins
J. A. Sobota (2009)
10.1007/s13346-010-0003-1
Non-viral systemic delivery of siRNA or antisense oligonucleotides targeted to Jun N-terminal kinase 1 prevents cellular hypoxic damage
S. Betigeri (2010)
10.1016/J.BBRC.2005.05.207
Improved intracellular delivery of glucocerebrosidase mediated by the HIV-1 TAT protein transduction domain.
K. Lee (2005)
10.1124/MI.6.2.7
Advanced drug delivery systems that target the vascular endothelium.
Bi-Sen Ding (2006)
Endothelium in health and disease.
W. Aird (2008)
10.1016/J.JPEDS.2005.12.014
Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study.
P. Harmatz (2006)
10.1016/J.JCONREL.2007.09.013
Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives.
R. C. Mundargi (2008)
10.1016/j.tibtech.2012.04.008
Colloidal systems for drug delivery: from design to therapy.
Mariana Beija (2012)
10.1038/mt.2009.53
The Pharmacological Chaperone N-butyldeoxynojirimycin Enhances Enzyme Replacement Therapy in Pompe Disease Fibroblasts
Caterina Porto (2009)
10.1016/j.biomaterials.2008.07.004
Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging.
Tapan Jain (2008)
10.1038/346425A0
Adhesion receptors of the immune system
T. Springer (1990)
10.1016/J.ADDR.2007.06.008
Endocytic mechanisms for targeted drug delivery.
Lisa Bareford (2007)
10.1016/j.addr.2012.08.012
Polymer therapeutics-prospects for 21st century: the end of the beginning.
R. Duncan (2013)
10.1016/j.jconrel.2010.01.036
Endocytosis of nanomedicines.
G. Sahay (2010)
10.1002/psc.2430
Peptide‐mediated cell penetration and targeted delivery of gold nanoparticles into lysosomes
Chaitali D Dekiwadia (2012)
10.1002/JBM.A.30348
Biological evaluation of calcium alginate microspheres as a vehicle for the localized delivery of a therapeutic enzyme.
C. Barrias (2005)
Andjelkovic, Brain endothelial cell-cell junctions: how to "open" the blood brain barrier
S. M. Stamatovic (2008)
10.1083/jcb.201208152
Lysosomal storage disorders: The cellular impact of lysosomal dysfunction
F. Platt (2012)
10.1016/S0022-2836(65)80093-6
Diffusion of univalent ions across the lamellae of swollen phospholipids.
A. Bangham (1965)
10.1083/JCB.109.6.2731
Distinct endocytotic pathways in epidermal growth factor-stimulated human carcinoma A431 cells [published erratum appears in J Cell Biol 1990 Mar;110(3):859]
M. A. West (1989)
10.1016/j.nano.2011.08.014
Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders.
Janet Hsu (2012)
10.1016/S0006-291X(03)01405-0
Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes.
M. Tóth (2003)
10.3233/BIR-2009-0544
Flow dynamics, binding and detachment of spherical carriers targeted to ICAM-1 on endothelial cells.
A. J. Calderon (2009)
Proteolytic cleavage of ICAM-1 by human neutrophil elastase.
B. Champagne (1998)
10.1083/jcb.200705060
Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway
Y. Zeidan (2008)
10.1152/AJPCELL.00099.2003
Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress.
S. Muro (2003)
10.1016/j.addr.2008.04.001
Materials for advanced drug delivery in the 21st century: a focus area for Advanced Drug Delivery Reviews.
H. Ghandehari (2008)
10.1016/J.JPEDS.2004.01.046
Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).
J. Wraith (2004)
10.1080/21688370.2016.1153568
Nanoparticle transport across the blood brain barrier
A. Grabrucker (2016)
10.1007/s13346-012-0072-4
Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders
S. Muro (2012)
10.1016/j.jconrel.2010.11.004
Endosomal escape pathways for delivery of biologicals.
Amir K. Varkouhi (2011)
10.1073/PNAS.0308728100
Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice.
J. LeBowitz (2004)
10.1021/mp500409y
Distinct Subcellular Trafficking Resulting from Monomeric vs Multimeric Targeting to Endothelial ICAM-1: Implications for Drug Delivery
Rasa Ghaffarian (2014)
10.1016/j.nbd.2011.01.021
Autophagy failure in Alzheimer's disease—locating the primary defect
R. Nixon (2011)
10.1515/BC.2008.162
Ceramide in bacterial infections and cystic fibrosis
H. Grassmé (2008)
10.1038/nbt1292
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung
P. Oh (2007)
10.1038/nrm3151
Molecular mechanism and physiological functions of clathrin-mediated endocytosis
H. McMahon (2011)
10.1038/mt.2010.78
Guanidinylated neomycin mediates heparan sulfate-dependent transport of active enzymes to lysosomes.
Stéphane Sarrazin (2010)
10.4161/auto.7.6.15812
V-ATPase engagement in autophagic processes
D. Mijaljica (2011)
10.1194/jlr.R046896
Lysosomal exocytosis and lipid storage disorders
M. Samie (2014)
10.1021/mp300293n
Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges.
R. Duncan (2012)
10.1016/0092-8674(87)90104-8
Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1)
S. D. Marlin (1987)
10.1124/jpet.111.185579
A Fibrinogen-Derived Peptide Provides Intercellular Adhesion Molecule-1-Specific Targeting and Intraendothelial Transport of Polymer Nanocarriers in Human Cell Cultures and Mice
C. Garnacho (2012)
10.1152/AJPLUNG.00533.2005
Endocytosis pathways in endothelium: how many?
R. Stan (2006)
10.1074/jbc.M510797200
Tumor Necrosis Factor-α-converting Enzyme (TACE/ADAM-17) Mediates the Ectodomain Cleavage of Intercellular Adhesion Molecule-1 (ICAM-1)*
N. Tsakadze (2006)
10.1002/wnan.73
New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders.
S. Muro (2010)
Receptor-Mediated Endocytosis and the Sorting of Internalized Proteins
H. Lodish (2000)
10.1016/S0091-6749(00)91292-2
864 Polarized secretion of chemokine RANTES and sICAM-1 from a bronchial epithelial cell line BEAS-2B
S. Kinjyo (2000)
10.1016/j.addr.2009.03.007
Magnetic nanoparticles for theragnostics.
V. Shubayev (2009)
10.1016/S0024-3205(01)01384-4
Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease.
F. Camargo (2001)
10.1089/DNA.1991.10.399
Molecular and cellular mechanisms of receptor-mediated endocytosis.
V. Brown (1991)
10.1016/J.SEMCDB.2007.07.003
Matrix metalloproteinases as modulators of inflammation.
A. M. Manicone (2008)
10.1016/S1734-1140(09)70004-0
ICAM-1 signaling in endothelial cells.
C. Lawson (2009)
Internalization of cholera toxin by different endocytic mechanisms.
M. Torgersen (2001)
10.1155/2011/160967
Effects of Polyethylene Glycol Spacer Length and Ligand Density on Folate Receptor Targeting of Liposomal Doxorubicin In Vitro
K. Kawano (2011)
Stimulation of tumor growth by human soluble intercellular adhesion molecule-1.
Y. S. Gho (2001)
10.1007/s00109-008-0309-3
Non-inhibitory antibodies impede lysosomal storage reduction during enzyme replacement therapy of a lysosomal storage disease
U. Matzner (2008)
10.1124/jpet.107.133298
Delivery of Acid Sphingomyelinase in Normal and Niemann-Pick Disease Mice Using Intercellular Adhesion Molecule-1-Targeted Polymer Nanocarriers
C. Garnacho (2008)
10.1016/j.addr.2012.09.036
Quantum dots as a platform for nanoparticle drug delivery vehicle design.
C. Probst (2013)
10.1016/j.ymgme.2015.05.013
Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency.
M. Wasserstein (2015)
10.1074/jbc.M110.141028
Differential Effects of Ceramide and Sphingosine 1-Phosphate on ERM Phosphorylation
D. Canals (2010)
10.1155/2012/429524
Parkinson's Disease and Autophagy
A. Sánchez-Pérez (2012)
Aminabhavi, Recent advances on chitosan-based micro- and nanoparticles in drug delivery
S. A. Agnihotri (2004)
10.1038/mt.2015.106
Arylsulfatase A Overexpressing Human iPSC-derived Neural Cells Reduce CNS Sulfatide Storage in a Mouse Model of Metachromatic Leukodystrophy.
J. Doerr (2015)
10.1083/JCB.93.1.135
Biosynthesis of lysosomal hydrolases: their synthesis in bound polysomes and the role of co- and post-translational processing in determining their subcellular distribution
MG Rosenfeld (1982)
10.1083/jcb.200407113
Clathrin- and caveolin-1–independent endocytosis
Eva-Maria Damm (2005)
10.1016/0014-2999(72)90134-3
Ethanol enhancement of blood-brain barrier permeability to catecholamines in chicks.
J. Hanig (1972)
10.1083/JCB.141.4.905
Filipin-dependent Inhibition of Cholera Toxin: Evidence for Toxin Internalization and Activation through Caveolae-like Domains
P. Orlandi (1998)
10.2174/138161211797247578
Gene therapy for lysosomal storage diseases: progress, challenges and future prospects.
S. Seregin (2011)
10.1007/s00018-009-0053-z
Nanocarriers’ entry into the cell: relevance to drug delivery
H. Hillaireau (2009)
10.1002/adhm.201500746
α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration.
I. Cabrera (2016)
10.1016/j.ymgme.2015.11.001
Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction.
P. Kishnani (2016)
10.1073/pnas.1307152110
Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor
Devin T. Wiley (2013)
10.1016/J.CHEMBIOL.2005.09.007
Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles.
A. Sawkar (2005)
10.1038/KI.1990.221
Differing regulation and function of ICAM-1 and class II antigens on renal tubular cells.
A. Jevnikar (1990)
10.1242/jcs.00840
Caveosomes and endocytosis of lipid rafts
B. Nichols (2003)
10.1093/HMG/DDM289
A block of autophagy in lysosomal storage disorders.
C. Settembre (2008)
10.1007/978-1-59745-194-9_14
Delivery of DNA into muscle for treating systemic diseases: advantages and challenges.
C. Trollet (2008)
10.1016/S0962-8924(03)00005-9
At the acidic edge: emerging functions for lysosomal membrane proteins.
E. Eskelinen (2003)
10.1093/ABBS/GMP031
The lysosome and neurodegenerative diseases.
L. Zhang (2009)
10.3109/15419069509081014
A distinct mRNA encoding a soluble form of ICAM-1 molecule expressed in human tissues.
T. Wakatsuki (1995)
10.1038/nn.2528
CARGO RECOGNITION FAILURE IS RESPONSIBLE FOR INEFFICIENT AUTOPHAGY IN HUNTINGTON’S DISEASE
M. Martinez-Vicente (2010)
Bayever, The status of hematopoietic stem cell transplantation in lysosomal storage disease
J. J. Malatack (2003)
10.1074/jbc.M112.357707
δ-Tocopherol Reduces Lipid Accumulation in Niemann-Pick Type C1 and Wolman Cholesterol Storage Disorders*
Miao Xu (2012)
10.1038/nrm1357
Endothelial cell–cell junctions: happy together
E. Dejana (2004)
10.1038/nrm1423
The cell biology of lysosomal storage disorders
A. Futerman (2004)
10.1089/HUM.2013.238
Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial.
TardieuMarc (2014)
10.1016/j.ymgmr.2014.08.004
Effects of intracerebroventricular administration of 2-hydroxypropyl-β-cyclodextrin in a patient with Niemann–Pick Type C disease
M. Matsuo (2014)
10.1084/jem.20102518
Trypanosoma cruzi subverts the sphingomyelinase-mediated plasma membrane repair pathway for cell invasion
M. C. Fernandes (2011)
10.1089/humc.2013.208
Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates.
Darren A Murrey (2014)
Enzyme-Replacement Therapies for Lysosomal Storage Diseases
T. Ratko (2013)
10.2174/1389200211314090004
Cellular targets and mechanisms in the cytotoxic action of non-biodegradable engineered nanoparticles.
E. Fröhlich (2013)
10.1002/9780470720745.CH8
Steps in the phosphorylation of the high mannose oligosaccharides of lysosomal enzymes.
S. Kornfeld (1982)
10.1083/JCB.131.1.69
Clathrin-independent pinocytosis is induced in cells overexpressing a temperature-sensitive mutant of dynamin
H. Damke (1995)
A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1.
R. Rothlein (1986)
Intercellular adhesion molecules and vascular cell adhesion molecule-1 and the kidney.
R. P. Wuthrich (1992)
10.1007/s00018-008-7470-2
Chemical chaperone therapy for GM1-gangliosidosis
Y. Suzuki (2008)
10.1166/JBN.2014.1718
Enhancing biodistribution of therapeutic enzymes in vivo by modulating surface coating and concentration of ICAM-1-targeted nanocarriers.
Janet Hsu (2014)
10.4161/fly.26630
Mutations in palmitoyl-protein thioesterase 1 alter exocytosis and endocytosis at synapses in Drosophila larvae
E. Aby (2013)
10.1385/1-59259-813-7:021
Characterization of endothelial internalization and targeting of antibody-enzyme conjugates in cell cultures and in laboratory animals.
S. Muro (2004)
10.1096/fj.04-2714fje
Protein transduction of Rab9 in Niemann‐Pick C cells reduces cholesterol storage
K. Narita (2005)
10.1007/springerreference_109779
[Niemann-Pick disease types A and B].
K. Ohno (1995)
Drug delivery and targeting.
R. Langer (1998)
Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity.
J. Becker (1991)
10.1016/j.ymgme.2008.08.004
Characterization of common SMPD1 mutations causing types A and B Niemann-Pick disease and generation of mutation-specific mouse models.
Iwan G. Jones (2008)
Bonifacino, Sorting of lysosomal proteins
T. Braulke (2009)
10.1016/j.devcel.2011.07.016
Transcriptional Activation of Lysosomal Exocytosis Promotes Cellular Clearance
D. Medina (2011)
10.1016/j.biomaterials.2010.06.038
Self-assembled nanoplatform for targeted delivery of chemotherapy agents via affinity-regulated molecular interactions.
Spencer Park (2010)
10.1038/35074539
Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER
L. Pelkmans (2001)
10.1007/0-306-47932-X_1
Challenges in polymer therapeutics: state of the art and prospects of polymer drugs.
A. Kabanov (2003)
10.1016/S0168-3659(99)00248-5
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.
H. Maeda (2000)
10.1001/JAMA.281.3.249
Prevalence of lysosomal storage disorders.
P. Meikle (1999)
10.1002/(SICI)1097-4547(19970201)47:3<341::AID-JNR12>3.0.CO;2-4
Delivery of liposome‐sequestered hydrophobic proteins to lysosomes of normal and batten disease cells
N. Ansari (1997)
10.1161/ATVBAHA.111.244186
Intercellular Adhesion Molecule 1 Engagement Modulates Sphingomyelinase and Ceramide, Supporting Uptake of Drug Carriers by the Vascular Endothelium
Daniel Serrano (2012)
10.1124/jpet.105.098970
Endothelial Targeting of High-Affinity Multivalent Polymer Nanocarriers Directed to Intercellular Adhesion Molecule 1
S. Muro (2006)
10.1006/BBRC.1999.0965
Release of soluble ICAM-1 from human lung fibroblasts, aortic smooth muscle cells, dermal microvascular endothelial cells, bronchial epithelial cells, and keratinocytes.
K. H. Leung (1999)
10.1074/JBC.M407167200
Macropinocytosis Is the Endocytic Pathway That Mediates Macrophage Foam Cell Formation with Native Low Density Lipoprotein*
H. Kruth (2005)
10.1021/nn505002w
Interference in Autophagosome Fusion by Rare Earth Nanoparticles Disrupts Autophagic Flux and Regulation of an Interleukin-1β Producing Inflammasome
Ruibin Li (2014)
10.1021/BC700227Z
PLGA nanoparticle--peptide conjugate effectively targets intercellular cell-adhesion molecule-1.
N. Zhang (2008)
10.1083/JCB.124.5.717
Phorbol myristate acetate-mediated stimulation of transcytosis and apical recycling in MDCK cells
M. Cardone (1994)
10.1021/nn500136z
Vascular Targeting of Nanocarriers: Perplexing Aspects of the Seemingly Straightforward Paradigm
Melissa D. Howard (2014)
10.1002/BIT.20625
Targeted ultrasound contrast agents: in vitro assessment of endothelial dysfunction and multi-targeting to ICAM-1 and sialyl Lewisx.
G. Weller (2005)
10.1371/journal.pone.0049635
Acidic Nanoparticles Are Trafficked to Lysosomes and Restore an Acidic Lysosomal pH and Degradative Function to Compromised ARPE-19 Cells
Gabriel C. Baltazar (2012)
10.1038/NRG1016
Enzyme replacement and enhancement therapies: lessons from lysosomal disorders
R. Desnick (2003)
10.1021/mp9003095
Immunoliposomes that target endothelium in vitro are dependent on lipid raft formation.
Rico C Gunawan (2010)
10.1016/s0021-9258(18)45483-x
Low density lipoprotein (LDL)-mediated suppression of cholesterol synthesis and LDL uptake is defective in Niemann-Pick type C fibroblasts.
L. Liscum (1987)
10.1016/J.BBAMCR.2005.11.007
Clathrin-independent endocytosis: new insights into caveolae and non-caveolar lipid raft carriers.
M. Kirkham (2005)
10.1186/1750-1172-8-15
Identification of a distinct mutation spectrum in the SMPD1 gene of Chinese patients with acid sphingomyelinase-deficient Niemann-Pick disease
H. Zhang (2013)
Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2).
R. Fridman (1995)
Treatment of lysosomal storage disorders : progress with enzyme replacement therapy.
M. Rohrbach (2007)
10.1038/nrd2368
Modelling of the blood–brain barrier in drug discovery and development
R. Cecchelli (2007)
10.1002/wnan.143
Overcoming in vivo barriers to targeted nanodelivery.
A. Chrastina (2011)
10.1007/s11095-013-1289-8
Specific Binding, Uptake, and Transport of ICAM-1-Targeted Nanocarriers Across Endothelial and Subendothelial Cell Components of the Blood–Brain Barrier
Janet Hsu (2013)
10.1091/MBC.E02-12-0809
Selective caveolin-1-dependent endocytosis of glycosphingolipids.
R. D. Singh (2003)
The uptake of enzymes into lysosomes: an overview.
E. Neufeld (1980)
10.1007/8904_2011_80
Molecular genetic characterization of novel sphingomyelin phosphodiesterase 1 mutations causing niemann-pick disease.
B. Tóth (2012)
10.1371/journal.pone.0015054
Cyclodextrin Induces Calcium-Dependent Lysosomal Exocytosis
F. Chen (2010)
10.1007/978-1-4899-2540-4_1
Historical Fragments; Methods; Some Terminology
E. Holtzman (1989)
10.3109/10611860903548354
Biopharmaceutical drug targeting to the brain
W. Pardridge (2010)
10.2337/db06-1694
Proteolytic Degradation of VE-Cadherin Alters the Blood-Retinal Barrier in Diabetes
D. Navaratna (2007)
10.1021/bc200336j
Screening and optimization of ligand conjugates for lysosomal targeting.
I. Meerovich (2011)
10.1080/15548627.2015.1136769
Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases
M. Bourdenx (2016)
10.1182/BLOOD.V98.3.688
Transendothelial migration of lymphocytes across high endothelial venules into lymph nodes is affected by metalloproteinases.
C. Faveeuw (2001)
10.1016/J.MOLMED.2003.08.004
Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder.
D. Brooks (2003)
Bi-directional induction of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 during T lymphoma/endothelial cell contact: implication of ICAM-1.
F. Aoudjit (1998)
10.1002/ar.20757
Molecular and Cellular Mechanisms of Ectodomain Shedding
K. Hayashida (2010)
10.1038/nrn1725
Storage solutions: treating lysosomal disorders of the brain
M. Jeyakumar (2005)
10.5966/sctm.2015-0373
Induced Pluripotent Stem Cells for Disease Modeling and Evaluation of Therapeutics for Niemann-Pick Disease Type A
Y. Long (2016)
10.1201/B18060-11
Endothelial Cell Adhesion Molecules and Drug Delivery Applications
Helim Aranda-Espinoza (2015)
10.1083/JCB1977OIA11
Uropod elongation is a common final step in leukocyte extravasation through inflamed vessels
Y. Hyun (2012)
10.2310/7290.2007.00005
Inflammation-Specific T1 Imaging Using Anti-Intercellular Adhesion Molecule 1 Antibody-Conjugated Gadolinium Diethylenetriaminepentaacetic Acid
Kyu-Sil Choi (2007)
10.1074/jbc.M113.474957
Ganglioside GM1-mediated Transcytosis of Cholera Toxin Bypasses the Retrograde Pathway and Depends on the Structure of the Ceramide Domain*
D. Saslowsky (2013)
10.1002/ana.20807
Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease
T. Fukuda (2006)
Adesnik, The biogenesis of membranes and organelles., in The Metabolic and Molecular Bases of Inherited Disease, C
D. Sabatini (2001)
10.1182/BLOOD-2006-03-010801
Low-dose therapy trumps high-dose therapy again in the treatment of Gaucher disease.
A. Zimran (2006)
10.1089/hum.2008.022
Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA.
S. Worgall (2008)
10.1016/J.DRUDIS.2006.10.013
Blood-brain barrier delivery.
W. Pardridge (2007)
10.1201/B19907-16
Endocytosis and the Endolysosomal Route in Drug Delivery
J. Rappaport (2016)
10.1186/1743-8977-9-20
Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity
S. Stern (2012)
10.2174/138161208784705504
Lysosomal storage diseases and the blood-brain barrier.
D. Begley (2008)
Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of fusions between the receptor-associated protein (RAP) and alpha-L-iduronidase or acid alpha-glucosidase.
W. Prince (2004)
10.1155/2014/823071
Endogenous Ceramide Contributes to the Transcytosis of oxLDL across Endothelial Cells and Promotes Its Subendothelial Retention in Vascular Wall
W. Li (2014)
10.2165/00019053-200725030-00003
Enzyme Replacement Therapy in Orphan and Ultra-Orphan Diseases
D. Moore (2012)
10.1021/BI980915E
Sphingomyelinase induces lipid microdomain formation in a fluid phosphatidylcholine/sphingomyelin membrane.
J. Holopainen (1998)
10.1016/S0300-9084(86)80004-9
Receptor-mediated endocytosis: the intracellular journey of transferrin and its receptor.
A. Dautry-Varsat (1986)
10.1038/gim.2015.24
Novel first-dose adverse drug reactions during a phase I trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann–Pick disease type B (acid sphingomyelinase deficiency)
M. Mcgovern (2016)
10.1016/J.BEJ.2012.05.003
Enzymatic characterization of highly stable human alpha-galactosidase A displayed on magnetic particles
José Luis Corchero (2012)
10.1161/STROKEAHA.114.005427
Cell-Culture Models of the Blood–Brain Barrier
Y. He (2014)
10.1007/s11095-008-9740-y
In Drug Delivery, Shape Does Matter
S. Mitragotri (2008)
10.1038/nbt.1484
Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment
J. Wang (2008)
10.1515/BCHM3.1994.375.7.447
The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts.
R. Hurwitz (1994)
10.1016/S0962-8924(00)01847-X
Jamming the endosomal system: lipid rafts and lysosomal storage diseases.
Kai Simons (2000)
10.1073/PNAS.80.8.2258
pH and the recycling of transferrin during receptor-mediated endocytosis.
A. Dautry-Varsat (1983)
10.1038/emboj.2010.237
Lysosomal fusion and SNARE function are impaired by cholesterol accumulation in lysosomal storage disorders
A. Fraldi (2010)
10.1021/nn404719c
Biological functionalization of drug delivery carriers to bypass size restrictions of receptor-mediated endocytosis independently from receptor targeting.
M. Ansar (2013)
10.1016/j.tins.2011.05.006
Clarifying lysosomal storage diseases
Mark L. Schultz (2011)
10.1073/pnas.251662398
Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: A pathway to overcome cell barriers to drug and gene delivery
D. Mcintosh (2002)
10.1056/NEJM197509252931304
A practical chromogenic procedure for the detection of homozygotes and heterozygous carriers of Niemann-Pick disease.
A. Gal (1975)
10.2147/IJN.S68685
Overendocytosis of gold nanoparticles increases autophagy and apoptosis in hypoxic human renal proximal tubular cells
F. Ding (2014)
10.1074/jbc.M110.134775
Exosome Secretion Ameliorates Lysosomal Storage of Cholesterol in Niemann-Pick Type C Disease*
K. Strauss (2010)
Kahari, Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets
P. Vihinen (2002)
10.1136/adc.2009.173419
The epidemiology of progressive intellectual and neurological deterioration in childhood
C. Verity (2009)
10.1111/j.2042-7158.1985.tb05051.x
The effect of non‐ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice
M. N. Azmin (1985)
10.1358/dot.2011.47.7.1608922
Velaglucerase alfa: a new option for Gaucher disease treatment.
A. Zimran (2011)
10.1016/j.jconrel.2008.06.007
Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes.
C. Garnacho (2008)
10.1152/physiol.00041.2009
Lysosomal storage disease: revealing lysosomal function and physiology.
E. Parkinson-Lawrence (2010)
10.5772/24366
Nanomedicine and Drug Delivery Strategies for Treatment of Genetic Diseases
J. Hsu (2011)
10.1002/ange.201600593
Compact, Polyvalent Mannose Quantum Dots as Sensitive, Ratiometric FRET Probes for Multivalent Protein–Ligand Interactions
Y. Guo (2016)
10.1016/S0169-409X(01)00141-7
Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo.
J. Schnitzer (2001)
10.1038/nature01451
Regulated portals of entry into the cell
S. Conner (2003)
10.1002/BIT.21602
Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood‐brain barrier
R. Boado (2008)
10.1021/nn305663e
A systematic analysis of peptide linker length and liposomal polyethylene glycol coating on cellular uptake of peptide-targeted liposomes.
J. F. Stefanick (2013)
10.5414/CPP47034
Disease pathogenesis explained by basic science: lysosomal storage diseases as autophagocytic disorders.
A. Ballabio (2009)
10.1016/J.BBAMCR.2005.06.009
Secrets of caveolae- and lipid raft-mediated endocytosis revealed by mammalian viruses.
L. Pelkmans (2005)
10.4049/jimmunol.1500702
Acid Sphingomyelinase–Derived Ceramide Regulates ICAM-1 Function during T Cell Transmigration across Brain Endothelial Cells
M. A. Lopes Pinheiro (2016)
10.1083/jcb.200102084
Clathrin-dependent and -independent internalization of plasma membrane sphingolipids initiates two Golgi targeting pathways
V. Puri (2001)
Targeting of protein kinase C-epsilon during Fcgamma receptor-dependent phagocytosis requires the epsilonC1B domain and phospholipase C-gamma1.
Keylon L. Cheeseman (2006)
10.1083/jcb.200112067
Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake
O. Meier (2002)
10.1002/JEMT.10089
Structure and function of endothelial caveolae
R. Stan (2002)
10.1186/1743-8977-10-35
Multi-walled carbon nanotubes induce human microvascular endothelial cellular effects in an alveolar-capillary co-culture with small airway epithelial cells
Brandi N. Snyder-Talkington (2013)
10.1021/nn305773f
Reduction of nanoparticle avidity enhances the selectivity of vascular targeting and PET detection of pulmonary inflammation.
Blaine Zern (2013)
10.2147/TACG.S57682
Recent advances in gene therapy for lysosomal storage disorders
D. Rastall (2015)
10.1002/wnan.1157
Recent advances in stealth coating of nanoparticle drug delivery systems.
Z. Amoozgar (2012)
10.1016/S0962-8924(02)02399-1
Endocytosis and sorting of glycosphingolipids in sphingolipid storage disease.
D. Marks (2002)
10.3892/ijmm.2012.1187
New strategies for the treatment of lysosomal storage diseases (review).
G. Parenti (2013)
10.1016/J.BIOMATERIALS.2006.05.013
Gene delivery to differentiated neurotypic cells with RGD and HIV Tat peptide functionalized polymeric nanoparticles.
J. Suk (2006)
10.1002/bit.24795
Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor
R. Boado (2013)
10.1186/1750-1172-8-29
Cost-effectiveness of enzyme replacement therapy for Fabry disease
S. Rombach (2013)
10.1523/JNEUROSCI.4785-13.2014
Comparison of Five Peptide Vectors for Improved Brain Delivery of the Lysosomal Enzyme Arylsulfatase A
A. Böckenhoff (2014)
10.1111/j.1582-4934.2007.00148.x
Clathrin-independent internalization and recycling
Q. Gong (2008)
10.1002/jps.22342
Controlling ligand surface density optimizes nanoparticle binding to ICAM-1.
A. Fakhari (2011)
10.1016/J.JPEDS.2004.02.048
Lipid abnormalities in children with types A and B Niemann Pick disease.
M. Mcgovern (2004)
10.1002/JPS.20457
Folate receptor-mediated drug targeting: from therapeutics to diagnostics.
A. Hilgenbrink (2005)
10.1021/nn304439f
Nanoparticle geometry and surface orientation influence mode of cellular uptake.
Heather L Herd (2013)
10.1016/j.jconrel.2016.07.042
Intra- and trans-cellular delivery of enzymes by direct conjugation with non-multivalent anti-ICAM molecules.
Rasa Ghaffarian (2016)
10.1016/j.jconrel.2012.06.007
Transport of nanocarriers across gastrointestinal epithelial cells by a new transcellular route induced by targeting ICAM-1.
Rasa Ghaffarian (2012)
10.1016/j.cellsig.2011.10.016
Cell surface ceramide controls translocation of transferrin receptor to clathrin-coated pits.
Abo Bakr Abdel Shakor (2012)
10.1098/RSTB.2003.1269
Enzyme replacement therapy: conception, chaos and culmination.
R. Brady (2003)
10.1038/mt.2008.127
Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers.
S. Muro (2008)
10.1007/s00253-016-7689-z
α-Galactosidase delivery using 30Kc19-human serum albumin nanoparticles for effective treatment of Fabry disease
Hong Jai Lee (2016)
Immunotargeting to ICAM-1 provides binding, internalization and lysosomal delivery of acid sphinomyelinase
S. Muro (2004)
Bright, Lysosomes: fusion and function
J. P. Luzio (2007)
10.1093/HMG/DDH067
Molecular pathophysiology of mucolipidosis type IV: pH dysregulation of the mucolipin-1 cation channel.
M. Raychowdhury (2004)
Virgin, Autophagy in immunity and inflammation
B. Levine (2011)
10.1152/AJPLUNG.2000.279.3.L419
Mechanisms regulating endothelial cell barrier function.
T. Stevens (2000)
Soluble intercellular adhesion molecule-1 (sICAM-1): an overview.
A. Witkowska (2004)
10.1007/s00441-008-0688-3
Endothelial transcytosis in health and disease
M. Simionescu (2008)
10.1242/jcs.00367
A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1
S. Muro (2003)
10.1128/JVI.00136-12
Ebolavirus Requires Acid Sphingomyelinase Activity and Plasma Membrane Sphingomyelin for Infection
M. Miller (2012)
10.1126/scitranslmed.3002230
Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
Y. J. Yu (2011)
10.1523/JNEUROSCI.0498-13.2013
CLN3 Loss Disturbs Membrane Microdomain Properties and Protein Transport in Brain Endothelial Cells
L. Tecedor (2013)
Biological aspects of ceramideenriched membrane domains
H. Grassme (2007)
10.1016/j.jconrel.2012.05.052
Challenges in design and characterization of ligand-targeted drug delivery systems.
S. Muro (2012)
10.1074/jbc.M205329200
Human Rhinovirus Selectively Modulates Membranous and Soluble Forms of Its Intercellular Adhesion Molecule–1 (ICAM-1) Receptor to Promote Epithelial Cell Infectivity*
S. Whiteman (2003)
10.1371/journal.pone.0156452
Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders
Marika Salvalaio (2016)
10.1007/s40259-014-0108-z
Elosulfase Alfa: A Review of Its Use in Patients with Mucopolysaccharidosis Type IVA (Morquio A Syndrome)
K. Lyseng-Williamson (2014)
10.1002/jgm.581
Gene therapy for lysosomal storage diseases: the lessons and promise of animal models
N. M. Ellinwood (2004)
10.1101/GAD.815400
Matrix metalloproteinases: effectors of development and normal physiology.
T. Vu (2000)
10.1016/J.YMTHE.2006.01.006
Gene therapy for lysosomal storage diseases.
M. Sands (2006)
10.1016/J.ADDR.2006.09.020
Thermo- and pH-responsive polymers in drug delivery.
D. Schmaljohann (2006)
10.1016/0005-2736(77)90028-1
Enzyme therapy. VI: Comparative in vivo fates and effects on lysosomal integrity of enzyme entrapped in negatively and positively charged liposomes.
L. D. Steger (1977)
The Hurler corrective factor. Purification and some properties.
R. Barton (1971)
10.1089/cbr.2009.0627
Affinity and avidity in antibody-based tumor targeting.
Stephen I. Rudnick (2009)
10.1016/0092-8674(95)90314-3
A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency
B. Schmidt (1995)
10.1042/BST0021014
α-Mannosidase in Zinc-Deficient Rats: Possibility of Liposomal Therapy in Mannosidosis
H. M. Patel (1974)
10.1016/J.NANO.2006.11.008
The present and future of nanotechnology in human health care.
S. Sahoo (2007)
Long-circulating and target-specific nanoparticles: theory to practice.
S. Moghimi (2001)
10.1182/BLOOD-2004-05-1714
ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs.
S. Muro (2005)
10.1038/ki.2011.301
Cysteamine therapy: a treatment for cystinosis, not a cure.
S. Cherqui (2012)
10.1016/j.stemcr.2015.02.022
Ex Vivo Gene Therapy Using Patient iPSC-Derived NSCs Reverses Pathology in the Brain of a Homologous Mouse Model
Tagan A. Griffin (2015)
10.1002/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T
Profile of endothelial and leukocyte activation in fabry patients
T. DeGraba (2000)
[Lysosomal storage diseases--an overview].
A. Kloska (2011)
10.1016/S0163-7827(03)00033-X
Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties.
S. Moghimi (2003)
10.1016/J.IJPHARM.2007.10.046
Gateways and tools for drug delivery: endocytic pathways and the cellular dynamics of cell penetrating peptides.
A. Jones (2008)
10.4161/auto.19469
Autophagy in lysosomal storage disorders
A. Lieberman (2012)
10.1146/ANNUREV.CB.08.110192.002001
The interaction of bacteria with mammalian cells.
S. Falkow (1992)
10.1002/iub.480
Targeted therapeutics and nanodevices for vascular drug delivery: Quo vadis?
V. Muzykantov (2011)
10.1073/PNAS.72.1.88
A general method for the introduction of enzymes, by means of immunoglobulin-coated liposomes, into lysosomes of deficient cells.
G. Weissmann (1975)
Torchilin, Lysosome-targeted octadecyl-rhodamine B-liposomes enhance lysosomal accumulation of 186 glucocerebrosidase in Gaucher's cells in vitro
R. Thekkedath (2013)
10.1016/j.biomaterials.2013.01.069
In vivo performance of polymer nanocarriers dually-targeted to epitopes of the same or different receptors.
Iason T. Papademetriou (2013)
10.1016/j.biomaterials.2015.07.043
Exploiting shape, cellular-hitchhiking and antibodies to target nanoparticles to lung endothelium: Synergy between physical, chemical and biological approaches.
Aaron C. Anselmo (2015)
10.1146/ANNUREV.BI.55.070186.003311
Acidification of the endocytic and exocytic pathways.
I. Mellman (1986)
10.1002/(SICI)1098-1136(199802)22:2<103::AID-GLIA1>3.0.CO;2-8
Cleavage of membrane‐associated ICAM‐1 from astrocytes: Involvement of a metalloprotease
P. Lyons (1998)
10.1371/journal.pone.0004792
A Plant-Derived Recombinant Human Glucocerebrosidase Enzyme—A Preclinical and Phase I Investigation
D. Aviezer (2009)
10.1016/0006-8993(89)91079-2
Sodium dodecylsulphate induces a breach in the blood-brain barrier and enables a West Nile virus variant to penetrate into mouse brain
D. Kobiler (1989)
10.1038/nrm1665
An emergency response team for membrane repair
P. L. McNeil (2005)
10.1146/ANNUREV.CELLBIO.12.1.575
Endocytosis and molecular sorting.
I. Mellman (1996)
10.1124/JPET.103.060236
Dexamethasone-Mediated Up-Regulation of the Mannose Receptor Improves the Delivery of Recombinant Glucocerebrosidase to Gaucher Macrophages
Yunxiang Zhu (2004)
10.1152/AJPLUNG.00311.2005
Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na+/H+ exchanger proteins.
S. Muro (2006)
10.1371/journal.pone.0106328
Different Contributions of Clathrin- and Caveolae-Mediated Endocytosis of Vascular Endothelial Cadherin to Lipopolysaccharide-Induced Vascular Hyperpermeability
Y. Zhang (2014)
Bello-Reuss, Kidney., in Intercelluar Signaling in Development and Disease
W. J. Arendshorst (2011)
10.1084/jem.20131660
Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants
N. Bien-ly (2014)
10.1038/8861
Action of BTN1, the yeast orthologue of the gene mutated in Batten disease
D. Pearce (1999)
10.1016/j.addr.2006.09.009
Multifunctional nanocarriers.
V. Torchilin (2006)
10.1091/mbc.E09-01-0005
Glycolipid Trafficking in Drosophila Undergoes Pathway Switching in Response to Aberrant Cholesterol Levels
R. Hortsch (2010)
10.2741/3795
Recent developments in lipid-based pharmaceutical nanocarriers.
T. Musacchio (2011)
Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction.
J. Becker (1993)
10.1073/PNAS.79.7.2291
Amantadine and dansylcadaverine inhibit vesicular stomatitis virus uptake and receptor-mediated endocytosis of alpha 2-macroglobulin.
R. Schlegel (1982)
10.1007/s11095-014-1531-z
Targeting, Endocytosis, and Lysosomal Delivery of Active Enzymes to Model Human Neurons by ICAM-1-Targeted Nanocarriers
Janet Hsu (2014)
10.1016/J.CYTO.2005.04.007
Soluble ICAM-1: a marker of vascular inflammation and lifestyle.
A. Witkowska (2005)
10.1021/ACS.BIOMAC.6B00493
How Carrier Size and Valency Modulate Receptor-Mediated Signaling: Understanding the Link between Binding and Endocytosis of ICAM-1-Targeted Carriers.
Daniel Serrano (2016)
10.1016/S0962-8924(00)01794-3
Regulated secretion of conventional lysosomes.
N. Andrews (2000)
10.1016/j.nano.2011.05.016
Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging.
S. Parveen (2012)
10.1126/SCIENCE.276.5311.428
Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin.
F. Platt (1997)
10.3109/1061186X.2010.550921
Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B
Alexander Koshkaryev (2011)
10.1007/s10545-012-9534-6
Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor
J. Papademetriou (2012)
10.13016/M2Z884
ROLE OF ICAM-1-MEDIATED ENDOCYTOSIS IN ENDOTHELIAL FUNCTION AND IMPLICATIONS FOR CARRIER-ASSISTED DRUG DELIVERY
D. Serrano (2014)
10.1248/bpb.b14-00726
Efficacy of 2-Hydroxypropyl-β-cyclodextrin in Niemann-Pick Disease Type C Model Mice and Its Pharmacokinetic Analysis in a Patient with the Disease.
Y. Tanaka (2015)
10.1021/bm2003384
pH-responsive polysaccharide-based polyelectrolyte complexes as nanocarriers for lysosomal delivery of therapeutic proteins.
M. I. Giannotti (2011)
10.1016/0304-4165(81)90474-8
Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation.
F. S. Furbish (1981)
10.1016/S0006-291X(85)80212-6
Enzyme replacement with liposomes containing beta-galactosidase from Charonia lumpas in murine globoid cell leukodystrophy (twitcher).
F. Umezawa (1985)
10.1142/9789814520652_0025
Lysosomes and Nanotherapeutics: Diseases, Treatments, and Side Effects
R. L. Manthe (2014)
10.1038/nrm2216
Pathways of clathrin-independent endocytosis
S. Mayor (2007)
10.1016/j.jconrel.2010.10.025
Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers.
A. J. Calderon (2011)
10.1016/S0753-3322(03)00065-9
Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions.
M. Jacob (2003)
10.1038/sj.onc.1205684
Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity
E. Fiore (2002)
10.1083/jcb.200404129
A transmigratory cup in leukocyte diapedesis both through individual vascular endothelial cells and between them
C. Carman (2004)
10.1074/JBC.M309465200
Mannose 6-Phosphate Receptor-mediated Uptake Is Defective in Acid Sphingomyelinase-deficient Macrophages
Rajwinder Dhami (2004)
10.1016/J.ADDR.2005.09.013
Transepithelial and endothelial transport of poly (amidoamine) dendrimers.
Kelly M. Kitchens (2005)
10.1021/mp500241y
Clathrin-Mediated Endocytosis Is Impaired in Type A–B Niemann–Pick Disease Model Cells and Can Be Restored by ICAM-1-Mediated Enzyme Replacement
J. Rappaport (2014)
10.1111/j.1471-4159.2007.05030.x
Cellular uptake and lysosomal delivery of galactocerebrosidase tagged with the HIV Tat protein transduction domain
Xianyang Zhang (2008)
10.1021/mp5005959
Altered Clathrin-Independent Endocytosis in Type A Niemann-Pick Disease Cells and Rescue by ICAM-1-Targeted Enzyme Delivery.
J. Rappaport (2015)
10.1186/1755-8417-1-6
Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts
M. Cardone (2008)
10.1042/BJ1280142PB
Lysosomal localization of enzyme-containing liposomes injected into rats.
G. Gregoriadis (1972)
10.1186/1743-8977-8-6
Inflammatory and cytotoxic responses of an alveolar-capillary coculture model to silica nanoparticles: Comparison with conventional monocultures
Jennifer Y Kasper (2010)
10.1620/TJEM.136.219
Delivery of fungal beta-galactosidase to rat brain by means of liposomes.
G. Takada (1982)
10.1016/j.jconrel.2010.10.031
Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.
Janet Hsu (2011)
10.1096/fj.04-2375com
A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder
G. Yam (2005)
10.1128/MMBR.49.3.298-337.1985
Comparative biology of intracellular parasitism.
J. Moulder (1985)
10.1517/14712598.2011.582036
Gene therapy for lysosomal storage disorders
A. Gritti (2011)
10.1016/j.jconrel.2011.09.067
Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1.
T. Bhowmick (2012)
10.1038/NPG.ELS.0006110
Lysosomal Transport Disorders
G. Mancini (2006)
10.3324/HAEMATOL.11193
Therapy of adult Gaucher disease.
Joerg Schmitz (2007)
10.1016/0304-4165(94)90113-9
Enhanced intracellular stability and efficacy of PEG modified dextranase in the treatment of a model storage disorder.
S. Mumtaz (1994)
10.1021/nn505073u
Ceria nanoparticles stabilized by organic surface coatings activate the lysosome-autophagy system and enhance autophagic clearance.
W. Song (2014)



Semantic Scholar Logo Some data provided by SemanticScholar